Irie Y, et al. - The effect of alogliptin (a dipeptidyl peptidase-4 inhibitor) on the longitudinal change was evaluated in gray-scale median (an index of the tissue characteristics of the carotid wall) in patients with type 2 diabetes (T2DM). During the 104-week treatment period, an improvement of tissue characteristics was noted in the carotid arterial wall in both the alogliptin treatment group and the conventional treatment group. They found no significant difference between the treatment groups.